Mr. Haeng Gyu Lee is a partner in Jipyong LLC’s Finance Group and heads the Capital Markets Team. He is one of Korea’s highest ranking attorneys in capital markets (IPOs and de-listing reviews), private equity funds, M&A, and overseas expansion of financial institutions, and has unparalleled experience in cross-border IPOs, GDR offerings and dual listings.
Mr. Lee’s most recent transaction highlight is his successful representation of SK Biopharmaceuticals in its recent IPO on the KOSPI market division of the Korea Exchange (KRX), the largest Korean IPO in 2020. As reflected in his significant track record, Mr. Lee is renowned for advising numerous companies that were first in their respective country of incorporation to be listed on the KRX, such as New Pride Corporation (US), Kolao Holdings (Laos), Fast Future Brands (Australia), LS Cable & System Asia (Vietnam). Mr. Lee is currently representing Prestige Bio Pharma, a Singaporean biosimilars company that is the first primary IPO of Singapore company on KRX and, Nanogen, Vietnam’s biosimilars company on its listing on the KRX. Mr. Lee also currently serves as a legal advisor for the KRX.
Korean Bar; New York Bar.
Columbia Law School (LL.M., 2007); Seoul National University (LL.B., 1996)